Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 11:9:977756.
doi: 10.3389/fnut.2022.977756. eCollection 2022.

Nigella sativa supplementation improves cardiometabolic indicators in population with prediabetes and type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

Saeede Saadati  1 , Kaveh Naseri  2 , Omid Asbaghi  3 , Khadijeh Abhari  4 , Pangzhen Zhang  5 , Hua-Bin Li  6 , Ren-You Gan  7
Affiliations
Review

Nigella sativa supplementation improves cardiometabolic indicators in population with prediabetes and type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

Saeede Saadati et al. Front Nutr. .

Abstract

Objective: Nigella sativa (N. sativa) from the family Ranunculaceae has medicinal properties. Previous studies have reported promising findings showing that N. sativa may benefit cardiometabolic health; however, current evidence on its cardiometabolic effects on those with prediabetes and type 2 diabetes mellitus (T2DM) is still unclear. Hence, we conducted a systematic review and meta-analysis to assess the efficacy of N. sativa on cardiometabolic parameters in population with prediabetes and T2DM.

Methods: PubMed/Medline, ISI Web of Science, Scopus, and Cochrane library were systematically searched up to June 20, 2022. Meta-analyses using random-effects models were used.

Results: Eleven randomized controlled trials (RCTs) were included in the meta-analysis. N. sativa intervention resulted in significant changes in fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), c-reactive protein (CRP), and malondialdehyde (MDA), without overall changes in glucose levels after oral glucose tolerance test (OGTT), fasting insulin, homeostatic model assessment of insulin resistance (HOMA-IR), triglyceride, high-density lipoprotein cholesterol (HDL-C), and body mass index (BMI) when compared with the control group. In subgroup analyses, N. sativa supplementation enhanced serum levels of HDL-C in subjects with baseline HDL-C lower than 40 mg/dL. Furthermore, HOMA-IR and BMI values decreased in the N. sativa-supplemented group compared with the control group, when the length of follow-up was more than 8 weeks and the dose was more than 1 g/day for N. sativa supplementation, respectively.

Conclusion: Our findings indicate that N. sativa supplementation may effectively improve cardiometabolic profiles in individuals with prediabetes and T2DM.

Keywords: Nigella sativa; cardiometabolic; diabetes mellitus; glycemic homeostasis; lipid profile; meta-analysis; prediabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The preferred reporting items for systematic review and meta-analysis (PRISMA) flowchart.
Figure 2
Figure 2
Forest plots of randomized controlled trials illustrating weighted mean difference (WMD) in biomarkers between the intervention and placebo groups for all eligible studies in overall analysis. (A) Fasting plasma glucose (FPG); (B) hemoglobin A1c (HbA1c); (C) total cholesterol (TC); (D) low-density lipoprotein cholesterol (LDL-C); (E) C-reactive protein (CRP); (F) Malondialdehyde (MDA).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, Abera SF, et al. . Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. (2017) 390:1151–210. 10.1016/S0140-6736(17)32152-9 - DOI - PMC - PubMed
    1. Afroz A, Alramadan MJ, Hossain MN, Romero L, Alam K, Magliano DJ, et al. . Cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries: a systematic review. BMC Health Serv Res. (2018) 18:972. 10.1186/s12913-018-3772-8 - DOI - PMC - PubMed
    1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. . Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. (2019) 157:107843. 10.1016/j.diabres.2019.107843 - DOI - PubMed
    1. Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. . IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. (2017) 128:40–50. 10.1016/j.diabres.2017.03.024 - DOI - PubMed
    1. Cho NH, Shaw J, Karuranga S, Huang Y, da Rocha Fernandes J, Ohlrogge A, et al. . IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for (2045). Diabetes Res Clin Pract. (2018) 138:271–81. 10.1016/j.diabres.2018.02.023 - DOI - PubMed
  NODES
INTERN 1
Project 2
twitter 2